Full-Time

Technical Application Scientist I

m/f/d

Updated on 9/3/2026

Revvity

Revvity

1,001-5,000 employees

Translational multi-omics and diagnostics provider

No salary listed

Hamburg, Germany

Hybrid

Frequent local travel is required within Northern Germany, with limited overnight travel.

Master's, PhD

Category
Solution Engineering (1)
Required Skills
CRM
Salesforce
Cell Biology

Get referred to Revvity

See people who can refer or advise you

Requirements
  • A PhD in Life Sciences or a related specialty such as biotechnology.
  • A Master's degree in biology or a related specialty, plus 3+ years of experience in an academic, industry, or clinical laboratory setting.
  • Fluent spoken and written German.
  • At least 2 years of direct experience with multi-parameter flow cytometry.
  • Experience with cellular assays, including in-vitro or primary-cell assays.
  • Molecular biology wet-lab experience, including Western blotting, polymerase chain reaction, enzyme-linked immunosorbent assay, or enzyme-linked immunospot assay.
Responsibilities
  • Develop in-person and remote relationships with key customers at assigned focus accounts.
  • Conduct and present technical seminars to laboratories, user groups, and local meetings.
  • Coordinate and perform product demonstrations, training, and technical support.
  • Provide direct sales support to customers in collaboration with the Global Sales Operations team.
  • Contribute to local business development related to product development, licensing, service or collaborative agreements, and other assigned responsibilities.
  • Represent BioLegend at user-group meetings, scientific conferences, and local shows as necessary.
  • Maintain a contact database in the customer relationship management system, Salesforce.
  • Manage expenses through monthly reports.
  • Prepare quarterly reports on territory performance and notable business developments at key accounts.
  • Report competitor activity and business opportunities as applicable.
  • Communicate self-development needs and develop long-term professional goals.
  • Travel as necessary, including frequent local travel within Northern Germany and limited overnight travel.
  • Perform other duties as assigned.
Desired Qualifications
  • Previous experience in a field-based role.
  • Previous industry work experience.
  • Research experience in cell biology, immunology, or cancer biology in an academic or industry setting.

Revvity provides health science solutions that span the full journey from discovery to development and from diagnosis to cure. It offers translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, and informatics, all delivered as integrated workflows and expert services. The company differentiates itself with an end-to-end platform that combines omics, imaging, biomarkers, and data analytics with specialized support to speed development. Its goal is to turn previously impossible healthcare outcomes into achievable results, advancing discovery, development, diagnosis and patient care.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2023

Get referred to Revvity

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $730 million; adjusted margins hit 28.9%.
  • Revvity raised 2026 guidance to $2.83-$2.86 billion revenue and $5.30-$5.40 EPS.
  • SuperFlex launched August 10, 2026, targeting underserved lower-volume prenatal labs immediately.

What critics are saying

  • Revvity is closing Boston and Lawrence sites, with 282 Massachusetts WARN layoffs through 2026.
  • China immunodiagnostics, about 6% of 2025 revenue, exits by end-2027.
  • T-SPOT A201 depends on 2027 regulatory approval; failure weakens infectious-disease growth.

What makes Revvity unique

  • Revvity bundles SuperFlex, T-SPOT A201, and LifeCycle into decentralized workflows.
  • Revvity's 2026 portfolio spans prenatal screening, TB automation, and biopharma informatics.
  • ACD/Labs acquisition and Signals software deepen Revvity's discovery-to-diagnosis platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Aug 13th, 2026
Revvity launches SuperFlex prenatal screening system for smaller labs

Revvity has launched SuperFlex, a compact prenatal screening system designed for small and mid-sized laboratories. The CE-IVDR-certified automated immunoassay instrument will initially be available in markets accepting CE-marked instruments, with Asia-Pacific expansion planned for late 2026. The benchtop immunoanalyser processes up to 60 tests per hour and delivers initial results in 14 minutes. It supports preeclampsia screening and prenatal testing using chemiluminescence immunoassay technology with 24 sample positions. SuperFlex aims to address financial and operational barriers in lower-volume testing environments by offering lower instrument costs, reduced maintenance expenses, and no reagent wastage. The platform integrates with Revvity's LifeCycle software. Revvity shares gained 1.6% following the announcement and have risen 21.8% year-to-date. The company has a market capitalisation of $12.91 billion.

Associated Press
Aug 10th, 2026
Revvity launches SuperFlex system to expand preeclampsia screening access in lower-volume labs

Revvity has launched the SuperFlex prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed for laboratories and clinics with lower-volume workflows. The system tests for preeclampsia, which affects 2% to 8% of pregnancies globally. The platform features affordable instrument costs with annual maintenance, no reagent wastage at low volumes, and delivers results in as little as 14 minutes per test. It includes a test menu for first- and second-trimester biochemical prenatal screening. The system will initially be available in markets accepting CE-marked instruments, with Asia-Pacific expansion planned for late 2026. Revvity reported 2025 revenue of $2.9 billion and employs approximately 11,000 people.

Yahoo Finance
Aug 10th, 2026
Upstart named buy amid 30.6% revenue growth forecast, Revvity and Northern Trust flagged as risky

Upstart, an AI-powered lending platform, stands out as a buy opportunity among profitable stocks, according to StockStory's analysis. The company uses machine learning to assess borrower risk for various loan types. Upstart's loan originations surged 54.3% over the past year, enabling increased fee collection and expansion into new markets like credit cards. The company's revenue is expected to grow 30.6% over the next 12 months, with free cash flow anticipated to turn positive next year. Meanwhile, StockStory advises caution on Revvity and Northern Trust. Revvity's sales declined 10.6% annually over five years, whilst Northern Trust's 6.9% annual revenue growth lagged behind financial peers. Both companies face headwinds despite maintaining profitability, with earnings pressures and market share concerns affecting their outlooks.

Yahoo Finance
Aug 10th, 2026
Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing

Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing Business Wire

Yahoo Finance
Aug 4th, 2026
Revvity reports $730M Q2 revenue, 4% growth, and raises full-year guidance

Revvity reported second quarter 2026 revenue of $730 million, with pro forma revenue of $711 million representing 4% growth and 3% organic growth. The company posted GAAP earnings per share from continuing operations of $0.48, while adjusted EPS reached $1.41. The company announced a definitive agreement to divest its China Immunodiagnostics business, which accounted for approximately 6% of total revenue in fiscal year 2025. The transaction is expected to close by the end of 2027, subject to regulatory approvals. Adjusted operating profit margin improved to 28.9%, up from 26.6% in the prior year period. GAAP operating income included $16 million in tariff-related refunds. Revvity raised its full-year guidance following the results.